| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11K | — | — |
| R&D Expense | $41K | — | — |
| SG&A Expense | $1.8M | — | +33.3% |
| Operating Income | -$1.9M | — | -43.1% |
| Net Income | -$1.9M | — | -25.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Current Assets | $1.1M | +261.6% | +68.7% |
| Total Assets | $2.6M | +46.4% | +98.4% |
| Current Liabilities | $15.9M | +19.9% | +108.1% |
| Total Liabilities | $17.0M | +16.7% | +109.7% |
| Stockholders' Equity | -$14.3M | -12.6% | -111.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.9M | — | -86.0% |
| Capital Expenditures | $9K | — | -93.2% |
| Investing Cash Flow | -$9K | — | +93.2% |
| Financing Cash Flow | $2.3M | — | +62.2% |
| Free Cash Flow | -$1.9M | — | -64.3% |